Table 1 Patient characteristics

 Female

n = 36

33,9 %

 Male

n = 70

66,1 %

 Age (median (range), years)

 Karnofsky index (median (range), %)

80 (60–100)

 Prior resection or radiofrequency ablation

n = 30

28 %

  Oxaliplatin (+5-fluorouracil)

n = 79

75 %

  Irinotecan (+5-fluorouracil)

n = 89

84 %

  Capecitabine

n = 27

25 %

  Bevacizumab

n = 67

63 %

  Cetuximab

n = 51

48 %

  Other

n = 7

7 %

Overall chemotherapy lines (median (range))

3 (1–5)

  1^st Line

n = 9

8 %

  2^nd Line

n = 35

33 %

  3^rd Line

n = 34

32 %

  4^th Line and beyond

n = 28

26 %

 UICC stage (median (range))

4 (1–4)

 Grading (median (range))

2 (1–4)

 Synchronous lymphatic metastases

n = 80

75 %

 Extrahepatic tumor sites prior to radioembolization

n = 30

28 %

  Solitary/oligonodular lung metastases

n = 1

1 %

  Diffuse lung metastases

n = 15

14 %

  Lymphatic metastases

n = 17

16 %

  Bone metastases

n = 3

3 %

 Hepatic tumor load (median (range), %)

 CEA serum level (median (range), ng/ml)

 CA19-9 serum level (median (range), U/ml)

Radioembolization procedures

n = 178

100 %

 Bilobar (total liver)

n = 12

7 %

 Unilobar

n = 52

30 %

 Sequential lobar

n = 114

64 %

 Treatment sessions per patient (median (range))

2 (1–5)

 Total activity per patient (median (range), MBq)